摘要
背景:如果仅仅基于传统的CV风险因素,心血管(CV)风险分层是次优的,因为具有相似风险特征的个体可能表现出不同的CV结果。因此,有必要确定新的风险因素。最近的研究强调内皮稳态在控制CV风险方面的相关性,但这些发现的临床相关性已经开始受到重视。深入了解参与这一现象的实际参与者将有助于识别新的生物标记物。内皮祖细胞(EPC)由于其在血管修复中的核心作用,有着广阔的应用前景。目的:由于过度炎症或免疫反应不平衡是EPC数量或功能改变的基础,可以推测这些介质可能被认为是危险分层的生物标志物。在本叙述性回顾中,我们的目的是汇编和批判性地评价目前所有将炎症和免疫途径与受损的EPC功能联系在一起的证据。结果:越来越多的证据表明,炎症驱动的传统CV危险因素与EPC功能障碍有关。衰老对EPC的影响与CXCR 4通路有关,而高血压则与肿瘤坏死因子α有关。观察到Akt/eNOS在糖尿病和血脂异常相关性状中的激活。炎症和氧化应激是EPC在吸烟过程中功能障碍的基础。结论:炎症和免疫网络可作为个性化药物方案中风险分层的可行生物标志物。
关键词: 内皮祖细胞,免疫系统,炎症,危险因素,血管修复,肿瘤坏死因子α。
Current Medicinal Chemistry
Title:EPC Dysfunction and Immune Networks: Translating Opportunities for Clinical Setting in Personalized Medicine
Volume: 25 Issue: 35
关键词: 内皮祖细胞,免疫系统,炎症,危险因素,血管修复,肿瘤坏死因子α。
摘要: Background: Cardiovascular (CV) risk stratification is suboptimal if solely based on traditional CV risk factors, since individuals with similar risk profiles could exhibit diverging CV outcomes. Thus, there is a need for new risk factors to be identified. Recent studies emphasize the relevance of the endothelial homeostasis in the control of CV risk, but the clinical relevance of these findings is starting to be appreciated. Gaining insight into the actual players involved in this phenomenon would lead to the identification of novel biomarkers. Due to their central role in vascular repair, Endothelial Progenitor Cells (EPC) are promising candidates for this issue.
Objective: Since excessive inflammation or imbalanced immune responses are known to underlie numerical or functional alterations of EPC, it can be speculated that these mediators may be considered as biomarkers for risk stratification. In the present narrative review, we aimed to compile and critically appraise all the current evidence linking inflammation and immune pathways with a compromised EPC functionality.
Results: A mounting body of evidence points to an inflammation-driven traditional CV risk factorsrelated EPC dysfunction. The effect of aging on EPC was associated with the CXCR4 pathway, whereas that of hypertension was related to TNFα. Activation of Akt/eNOS was observed in response to diabetes- and dyslipidemia-related traits. Inflammation and oxidative stress underlie the EPC dysfunction during smoking.
Conclusion: Inflammatory and immune networks can be proposed as feasible biomarkers for risk stratification in personalized medicine schemes.
Export Options
About this article
Cite this article as:
EPC Dysfunction and Immune Networks: Translating Opportunities for Clinical Setting in Personalized Medicine, Current Medicinal Chemistry 2018; 25 (35) . https://dx.doi.org/10.2174/0929867324666170606101823
DOI https://dx.doi.org/10.2174/0929867324666170606101823 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Supplementation of Creatine and Ribose Prevents Apoptosis and Right Ventricle Hypertrophy in Hypoxic Hearts
Current Pharmaceutical Design Pharmaceutical Care: Past, Present and Future
Current Pharmaceutical Design Potential Impact of Genetic Variants in Nrf2 Regulated Antioxidant Genes and Risk Prediction of Diabetes and Associated Cardiac Complications
Current Medicinal Chemistry Hypertension: Quo Vadis?
Current Vascular Pharmacology Vitamin D in COPD - A Pleiotropic Micronutrient in a Multisystem Disease
Current Respiratory Medicine Reviews The Role of Melanocortin Peptides and Receptors in Regulation of Energy Balance
Current Pharmaceutical Design Determination of Bioactive Constituents in Traditional Chinese Medicines by CE with Electrochemical Detection
Current Medicinal Chemistry Quality Control of Fingerprint of Radix Astragali by High-Performance Liquid Chromatography Coupled with Chemometric Methods
Current Pharmaceutical Analysis MDMA Toxicity and Pathological Consequences: A Review About Experimental Data and Autopsy Findings
Current Pharmaceutical Biotechnology Neurovascular Mechanisms of Hypertension in Pregnancy
Current Neurovascular Research Beta-Blockers: Current State of Knowledge and Perspectives
Mini-Reviews in Medicinal Chemistry Inflammation in Hypertension: Current Therapeutic Approaches
Current Pharmaceutical Design Postprandial Glucose - A Potential Therapeutic Target to Reduce Cardiovascular Mortality
Current Vascular Pharmacology Hepatic Elimination of Drugs in Gestational Diabetes
Current Clinical Pharmacology The Rapidly Changing Composition of the Global Street Drug Supply and its Effects on High-risk Groups for COVID-19
Current Psychopharmacology Obesity-Induced Hypertension: New Insights
Current Pharmaceutical Design Vascular Calcifications in Chronic Kidney Disease: Are There New Treatments?
Current Vascular Pharmacology Gender Differences in Atrial Fibrillation: A Review of Epidemiology, Management, and Outcomes
Current Cardiology Reviews Modulation of P2 Receptors on Pancreatic β-cells by Agonists and Antagonists: A Molecular Target for Type 2 Diabetes Treatment
Current Diabetes Reviews Enhancement of Solubility and Permeability of Candesartan Cilexetil by Using Different Pharmaceutical Interventions
Current Drug Delivery